| Rosemary Kahale, | |
|
125 N Central Ave, Glendale, CA 91203-2502 | |
| (818) 637-2758 | |
| Not Available |
| Full Name | Rosemary Kahale |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 125 N Central Ave, Glendale, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013483148 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 78309 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rosemary Kahale, 5272 Castle Rd, La Canada Flintridge, CA 91011-1316 Ph: (818) 389-3590 | Rosemary Kahale, 125 N Central Ave, Glendale, CA 91203-2502 Ph: (818) 637-2758 |
News Archive
With Election Day less than a month away, a new West Health-Gallup national survey finds more Americans trust former Vice President Joe Biden than President Donald Trump to efficiently lead the U.S. healthcare system through the COVID-19 pandemic.
"Developing countries will bear 60 percent of the world's cancer burden by 2020 and 70 percent by 2030," according to a report released Thursday during the World Cancer Congress in Shenzhen, China, Reuters reports. These countries also lack the necessary "infrastructure … to prevent cancer, diagnose it early or provide long-term treatment, according to CanTreat International, which comprises experts from leading international cancer organizations," the news service writes.
Drug delivery into muscle using an autoinjector, akin to the EpiPen used to treat serious allergic reactions, is faster and may be a more effective way to stop status epilepticus, a prolonged seizure lasting longer than five minutes, according to a study sponsored by the National Institutes of Health. Status epilepticus is a potentially life-threatening emergency that causes 55,000 deaths each year.
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The University of Texas MD Anderson Cancer Center.
› Verified 1 days ago
Annie Ahhyun Kim, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3943 San Fernando Rd, Glendale, CA 91204 Phone: 818-549-2270 | |
Dr. Linda Kalamkeryan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 600 W Stocker St, 105, Glendale, CA 91202 Phone: 818-433-8379 | |
Dr. Jane Kyun Lee, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1509 Wilson Ter, Glendale, CA 91206 Phone: 818-409-8000 | |
Anna Arutunyan, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1122 E Broadway, Glendale, CA 91205 Phone: 818-547-0170 | |
Dr. Monica Natalia Macias, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1509 Wilson Terrace, Glendale, CA 91206 Phone: 818-409-8140 | |
Arash Akmal, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3452 Country Club Dr, Glendale, CA 91208 Phone: 310-463-7326 |